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Abstract 
Nanotechnology is a developing area in science and technology that is being widely 
explored during the last decade and is one of the most important areas related to drug 
delivery, cancer treatment and diagnosis. The development of nanocarriers that can offer 
multiple advantages and a wide range of solutions for drug delivery and imaging 
properties is interesting and provides challenges and great benefits if well accomplished. 
Therefore, the aim of this study was to design a nanocarrier capable of transporting a 
therapeutic agent while providing imaging information regarding the environment of the 
cancer site.  
PLGA nanoparticles and AuNPs were developed with the aim to form a multiple functional 
nanoparticle, capable of therapeutic effect by transferring light triggered to heat, offering 
targeted treatment. The nanoparticles were developed and their cytotoxicity, transfection 
and microscopy assays were performed, in order to evaluate the nanoparticles’ 
characteristics and their therapeutic potential.  
Monodispersed AuNPs synthesized at room temperature by simultaneously using two 
reducing agents (Sodium citrate and Sodium borohydride), showed to be more stable and 
reproducible when compared to those prepared by the conventional method. The adopted 
preparation technique of the organic biodegradable PLGA NPs offers better control over 
size, polydispersity index and surface charge, allowing modification of its surface with the 
cationic polymers chitosan or protamine and incorporation of QDs. The cytotoxicity 
analysis of the prepared nanocarriers showed no remarkable toxic effects to HeLa cells in 
the conditions of the assay. The cationic PLGA NPs showed good nucleic acid 
complexation ability although did not show good transfection potential.  
The utilization of the prepared nanocarriers has to be investigated further in detail.  
 
 
 
Keywords: gold nanoparticles, PLGA nanoparticles, Quantum dots, nanocarriers, 
cytotoxicity, transfection, complexation, pDNA, siRNA, SPT, FCS 
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Resumo 
A Nanotecnologia é uma área da ciência e tecnologia em franco desenvolvimento, tendo-
se assistido na última década a uma expansão impressionante do seu âmbito de 
aplicação. Nomeadamente no âmbito da oncologia, é considerada uma das mais 
importantes áreas relacionadas com a libertação de fármacos e com o tratamento e 
diagnóstico do cancro. O desenvolvimento de nanotransportadores pode oferecer 
múltiplas vantagens e soluções para esta temática, potencialmente muito interessantes e 
desafiantes, trazendo grandes benefícios em caso de sucesso.  
Assim sendo, o objectivo deste estudo foi desenhar um nanotransportador capaz de 
libertar um agente terapêutico e ao mesmo tempo fornecer informação relativa ao 
ambiente circundante da localização do cancro. 
Nanopartículas de PLGA e de ouro foram desenvolvidas com o objectivo de criar uma 
nanopartícula multifuncional, capaz de produzir efeitos terapêuticos ao ser activada por 
luz pulsada em locais alvo. As nanopartículas foram desenvolvidas e a sua citotoxicidade 
e eficiência de transfecção foram testadas, bem como realizados ensaios de microscopia, 
para avaliar as características das mesmas e o seu potencial terapêutico. 
Nanopartículas de ouro monodispersas foram sintetizadas à temperatura ambiente, 
utilizando simultaneamente dois agentes reductores (citrato de sódio e boro-hidreto de 
sódio) que demonstraram ser o método mais estável e reprodutível de preparação das 
nanopartículas, em comparação com o método tradicional. A técnica de preparação 
adoptada para a formação de nanopartículas orgânicas e biodegradáveis de PLGA, 
oferece um melhor controlo relativamente ao seu tamanho, índice de polidispersão e 
carga da superfície, permitindo a modificação da sua superfície exterior com os polímeros 
catiónicos quitosana ou protamina e ainda a incorporação de QDs. A análise citotóxica 
efectuada dos nanotransportadores preparados não demonstrou efeitos tóxicos 
significativos nas células HeLa nas condições testadas. As nanopartículas de PLGA 
catiónicas mostraram uma boa capacidade de complexação de ácidos nucleicos, no 
entanto, não mostraram uma boa eficiência de transfecção. 
A utilização das nanopartículas preparadas deve ser investigada em detalhe. 
 
Palavras-chave: nanopartículas de ouro, nanopartículas de PLGA, Quantum dots, 
nanotransportadores, citotoxicidade, transfecção, complexação, pDNA, siRNA, SPT, FCS 
vii 
 
  
viii 
 
Table of Contents 
Acknowledgments ............................................................................................................ iv 
Abstract ............................................................................................................................. v 
Resumo ............................................................................................................................ vi 
List of Figures ................................................................................................................... xi 
List of Tables ................................................................................................................... xiii 
Abbreviations and symbols .............................................................................................. xiv 
1. Introduction ................................................................................................................... 1 
1.1 Size of nanoparticles ................................................................................................ 2 
1.2 Shape of nanoparticles ............................................................................................ 2 
1.3 Surface charge of nanoparticles............................................................................... 2 
1.4 Hydrophobic/hydrophilic character of nanoparticles ................................................. 3 
1.5 Mechanical flexibility of nanoparticles ...................................................................... 3 
1.6 Types of nanoparticles ............................................................................................. 3 
1.6.1 Carbon-based nanocarriers ............................................................................... 4 
1.6.2 Dendrimers ........................................................................................................ 4 
1.6.3 Lipid-based nanocarriers ................................................................................... 5 
1.7 Polymer based nanocarriers .................................................................................... 5 
1.7.1 Poly (lactic-co-glycolic acid) nanoparticles ......................................................... 7 
1.8 Metallic nanoparticles .............................................................................................. 9 
1.8.1 Gold nanoparticles .......................................................................................... 10 
1.9 Multifunctional nanoparticles .................................................................................. 11 
1.10 Stimuli-responsive nanocarriers ........................................................................... 13 
1.11 Scope and aims ................................................................................................... 13 
2. Materials and Methods ................................................................................................ 15 
2.1 Buffers ................................................................................................................... 15 
2.1.1 Hepes buffer .................................................................................................... 15 
2.1.2 TBE buffer ....................................................................................................... 15 
2.1.3 Flow buffer ...................................................................................................... 15 
2.2 Chemicals .............................................................................................................. 15 
2.3 Equipments ............................................................................................................ 16 
2.4 Preparation of gold nanoparticles (AuNPs) ............................................................ 16 
2.4.1 Preparation of AuNPs using sodium citrate as reducing agent ........................ 16 
2.4.2 Preparation of AuNPs using sodium citrate and sodium borohydride ............... 17 
2.5 Preparation of PLGA – poly(lactic-co-glycolic acid) Nanoparticles ......................... 17 
ix 
 
2.5.1 Preparation of PLGA NPs ................................................................................ 17 
2.5.2 Preparation of PLGA NPs conjugated with chitosan and protamine ................. 17 
2.5.3 Preparation of PLGA NPs with Quantum Dots (QDs) ...................................... 18 
2.6 Dynamic light scattering (DLS) of the NPs ............................................................. 18 
2.7 UV-Visible absorption of the NPs suspensions ...................................................... 18 
2.8 Plasmid Purification ............................................................................................... 18 
2.9 Gel Electrophoresis of the nanoparticles complexed with pDNA ............................ 19 
2.9.1 Complexation of the cationic nanoparticles with pDNA .................................... 19 
2.10 Cell culture for cytotoxicity and transfection evaluation ........................................ 20 
2.11 Cell viability assay: MTT assay ............................................................................ 21 
2.12 In vitro Transfection of NPs complexed with pDNA .............................................. 23 
2.13 Evaluation of NPs diffusion by single particle tracking (SPT) ............................... 23 
2.14 Evaluation of siRNA release from the NPs by fluorescence correlation 
spectroscopy (FCS) ..................................................................................................... 24 
3. Results ........................................................................................................................ 25 
3.1 Gold nanoparticles ................................................................................................. 25 
3.1.1 Dinamyc Light Scattering (DLS) .......................................................................... 25 
3.1.2 UV-Vis absorption of gold nanoparticles .......................................................... 26 
3.2 PLGA nanoparticles ............................................................................................... 26 
3.2.1 DLS of PLGA NPs ........................................................................................... 26 
3.2.2 Surface modification of PLGA NPs .................................................................. 27 
3.3 Evaluation of complexation potential between pDNA and cationic PLGA NPs by gel 
electrophoresis ............................................................................................................ 28 
3.3.1 Complexation potential between pDNA and chitosan coated PLGA NPs ......... 28 
3.3.2 Complexation potential between pDNA and protamine coated PLGA NPs ...... 29 
3.4 Cytotoxicity evaluation of NPs ................................................................................ 30 
3.4.1 Cytotoxicity of PLGA NPs ................................................................................ 30 
3.4.2 Cytotoxicity of chitosan coated PLGA NPs ...................................................... 31 
3.4.3 Cytotoxicity of protamine coated PLGA NPs .................................................... 31 
3.5 Transfection efficiency of cationic PLGA NPs ........................................................ 32 
3.6 Fluorescence correlation spectroscopy (FCS) of cationic PLGA NPs ..................... 32 
3.7 Single Particle Tracking (SPT) of cationic PLGA NPs ............................................ 37 
3.8 Incorporation of Quantum Dots in PLGA NPs ........................................................ 37 
3.8.1 Dinamyc light scattering and UV-Vis measurements ....................................... 37 
3.9 Complexation of pDNA with the cationic PLGA QDs NPs ...................................... 40 
3.9.1 Chitosan coated PLGA QDs NPs .................................................................... 40 
x 
 
3.9.2 Protamine coated PLGA QDs NPs .................................................................. 41 
3.10 Cytotoxicity of the PLGA QDs NPs ...................................................................... 41 
3.11.1 Cytotoxicity of chitosan coated PLGA QDs NPs ............................................ 42 
3.11.2 Cytotoxicity of protamine coated PLGA QDs NPs .......................................... 43 
4. Discussion ................................................................................................................... 44 
5. Conclusions ................................................................................................................. 47 
References ...................................................................................................................... 48 
Supplement 1 .................................................................................................................. 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
List of Figures 
 
Figure 1. Some types of nanoparticles used for drug delivery: (a) liposome; (b) dendrimer; 
(c) functionalized polymer; (d) micelle. Adapted from Cole et al. 2015............................... 3 
Figure 2. Scheme of a theranostic nanoparticle. Adapted from Cole et al. 2015 ............. 12 
Figure 3. Structural formula of HAuCl4 and Sodium citrate ............................................. 16 
Figure 4. Addition of the PLGA solution dropwise to water, forming the nanoparticles .... 17 
Figure 5. Structures of MTT and colored formazan product. Adapted from Riss et al. 2004
 ........................................................................................................................................ 22 
Figure 6. UV-Vis spectrum of AuNPs reduced with Sodium citrate (a); UV-Vis spectrum of 
AuNPs reduced with Sodium citrate and NaBH4 (b) ........................................................ 26 
Figure 7. Sizes of different PLGA NPs with different concentrations of PLGA solution ... 26 
Figure 8. Average size of PLGA NPs and PLGA NPs positively coated with Chitosan or 
Protamine ........................................................................................................................ 27 
Figure 9. Average Zeta-potencial of PLGA NPs and PLGA NPs positively coated with 
Chitosan or Protamine ..................................................................................................... 28 
Figure 10. Photo of Gel Electrophoresis of pDNA with PLGA Chitosan NPs ................... 29 
Figure 11. Photo of Gel Electrophoresis of pDNA with PLGA Protamine NPs................. 29 
Figure 12. Percentage of viability of HeLa cells after exposure to PLGA NPs ................. 30 
Figure 13. Percentage of viability of HeLa cells after exposure to PLGA Chitosan NPs .. 31 
Figure 14. Percentage of viability of HeLa cells after exposure to PLGA Protamine NPs 31 
Figure 15. Transfection efficiency of different PLGA NPs ............................................... 32 
Figure 16. Fluorescence intensity of free labeled siRNA (A); labeled siRNA + PLGA 
Chitosan (B); labeled siRNA + PLGA Chitosan after 1 h (C); labeled siRNA + PLGA 
Chitosan after 2 h (D); labeled siRNA + PLGA Chitosan after 24 h (E) ............................ 34 
Figure 17. Fluorescence intensity of labeled siRNA + PLGA Protamine NPs (A); labeled 
siRNA + PLGA Protamine NPs after 1 h (B); labeled siRNA + PLGA Protamine NPs after 
2 h (C); labeled siRNA + PLGA Protamine after 24 h (D) ................................................ 35 
Figure 18. Percentage of release of siRNA over time ..................................................... 36 
Figure 19. SPT analysis of PLGA + Protamine NPs complexed with pDNA .................... 37 
Figure 20. Average size of PLGA QDs NPs .................................................................... 38 
Figure 21. Average zeta-potential of PLGA QDs NPs ..................................................... 38 
Figure 22. Average size of PLGA QDs NPs positively coated with Chitosan or Protamine
 ........................................................................................................................................ 39 
Figure 23. Average Zeta-potencial of PLGA QDs NPs positively coated with Chitosan or 
Protamine ........................................................................................................................ 39 
xii 
 
Figure 24. UV-Vis spectrum of PLGA NPs with different volumes of QDs ....................... 40 
Figure 25. Photo of Gel Electrophoresis of pDNA with PLGA QDs Chitosan NPs ........... 40 
Figure 26. Photo of Gel Electrophoresis of pDNA with PLGA QDs Protamine NPs ........ 41 
Figure 27. Percentage of viability of HeLa cells after exposure to PLGA QDs NPs ......... 42 
Figure 28. Percentage of viability of HeLa cells after exposure to PLGA QDs Chitosan 
NPs ................................................................................................................................. 42 
Figure 29. Percentage of viability of PLGA QDs Protamine NPs ..................................... 43 
 
  
xiii 
 
 List of Tables 
 
Table 1 - Complexation volumes used for gel electrophoresis ........................................ 20 
Table 2 - Complexation concentrations used for gel electrophoresis ............................... 20 
Table 3 - Results of the size measurements of different AuNPs formed in different 
conditions using DLS ....................................................................................................... 25 
Table 4 - DLS measurements of AuNPs formed using Sodium citrate in different 
concentrations and temperatures .................................................................................... 56 
Table 5 - DLS measurements of AuNPs formed using Sodium citrate and NaBH4 in 
different concentrations and temperatures ...................................................................... 57 
Table 6 - DLS measurements of AuNPs formed using NaBH4 in different concentrations 
and temperatures ............................................................................................................ 62 
Table 7 - DLS measurements of AuNPs formed using NaBH4 and CTAB in different 
concentrations and temperatures .................................................................................... 62 
Table 8 - DLS measurements of AuNPs formed using bPEI in different concentrations and 
temperatures ................................................................................................................... 63 
Table 9 - DLS measurements of AuNPs formed using Oleic acid or Olive oil in different 
concentrations and temperatures .................................................................................... 63 
Table 10 - DLS measurements of AuNPs formed using NaBH4 and Alginic acid in different 
concentrations and temperatures .................................................................................... 64 
  
xiv 
 
Abbreviations and symbols 
 
µL-  microliter 
µM-  micromolar 
Au-  bulk gold 
AuNPs- gold nanoparticles 
bPEI-  branched Polyethylenimine  
BSA-  bovine serum albumin 
CCM-  cell culture medium 
cDNA-  complementary DNA 
CO2-  carbon dioxide 
CT-  computer tomography 
CTAB-  cetyltrimethylammonium bromide 
DLS-  dynamic light scattering 
DMEM- Dulbecco’s modified Eagle’s medium 
DMSO- dimethyl sulfoxide 
DNA-  deoxyribonucleic acid 
EDC-  N-3-dimethylaminopropyl-N-ethylcarbodiimide hydrochloride 
EDTA-  ethylenediaminetetraacetic acid 
EPR-  enhanced permeability and retention 
EtOH-  ethanol 
FCS-  fluorescence correlation microscopy 
GFP-  green fluorescence protein 
GIT-  gastrointestinal tract 
GO-  graphene oxide 
HAuCl4- choloauric acid 
HEPES- N-2-hydroxyethylpiperazine-N’-2-ethanosulfonic acid 
LB-  lysogeny broth 
MTT-  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
xv 
 
NaBH4- sodium borohydride 
NaCl-  sodium chloride 
NHS-  N-hydroxysulfosuccinimide sodium salt 
NIR-  near infrared 
nm-  nanometer 
NPs-  nanoparticles 
PAC-  poly-alkyl-cyanoacrylates 
PAMAMs- Poly(amidoamine) 
PBS-  phosphate buffered saline 
PCL-  poly-ε-caprolactone 
PDI-  polydispersity index 
pDNA-  plasmid DNA 
PEG-  polyethylene glycol 
PEI-  polyethylenimine 
PFA-  paraformaldehyde 
PLA-  polylactic acid 
PLGA-  poly(lactic-co-glycolic acid) 
QDs-  Quantum dots 
RES -  reticuloendothelial system 
RNA-  ribonucleic acid 
RNAi-  RNA interference 
ROS-  reactive oxygen species 
siRNA- small interference RNA 
SLN-   solid lipid nanoparticles 
T/E-  trypsine/EDTA 
TBE-  tris base EDTA buffer 
TOAB-  tetraoctylammonium bromide 
UV-Vis- ultraviolet visible 
xvi 
 
W/O/W- water/oil/water 
 
 
Introduction  
 
1 
 
1. Introduction 
Nanotechnology is a developing area in science and technology that is being widely 
explored during the last decade and is one of the most important areas related to drug 
delivery, cancer treatment and diagnosis. The potential of this field is applied to multiple 
circumstances and the opportunities to improve the current state of pharmaceutics are 
endless (1). The need for novel ways to efficiently deliver drugs was raised and 
nanocarriers are a possible answer to this problem. Capable of targeting delivery, the use 
of these carriers may diminish the amount of drug lost in nonspecific cells and tissue 
biodistribution, where some of them are rapidly cleared from the body (2). Nanoparticles 
appear as a possibility to alter the pharmacokinetic profile of drugs and their toxicity, 
improving the therapeutic index (3).  
As drug delivery vehicles, it is expected that these carriers possess some characteristics 
like drug entrapment, immune system escape, extending the circulation time, targeting to 
the diseased site, avoiding most healthy organs and release the drug (4). These key 
factors allow the effective delivery of the drug to the target site.   
The journey that a drug carrier has to pass from the moment where it is introduced in the 
organism until reaching the final target is complex, depending on many different factors. 
The interaction between the drug carriers and the reticuloendothelial system (RES) will 
determine if it will arrive to the final destination or not. It may be cleared by phagocytic 
cells as macrophages or filtered in the spleen or kidneys (5). Usually, the traditional drug 
delivery routes have a poor pharmacokinetic profile leading to a rapid clearance of the 
drug and therefore, requiring high dosages to intensify the effect and have a more efficient 
response.  
If the carrier is able to overcome the steps that lead to poor biodistribution, it can adhere 
at the desired site in the vasculature or permeate through the vasculature until the desired 
site (5). Then diffusion of the carrier through the interstitial space and endocytosis can 
occur.     
The physical and chemical characteristics of nanoparticles may affect their translocation 
through the biological barriers and distribution in the organism and also their toxicity (6, 7). 
These characteristics are size, shape, surface properties, surface coating, composition, 
solubility, aggregation/agglomeration, particle uptake, presence of transition metals 
related to the nanoparticles (7). 
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1.1 Size of nanoparticles  
The size is directly related to the cellular uptake rate of the nanoparticles and to the 
circulation time it spends in the bloodstream (8). Smaller nanoparticles, less than 10nm in 
diameter, are believed to be cleared via glomerular filtration in the kidneys, whereas larger 
nanoparticles, more than 100nm, are probably cleared through the Kupffer cells in the 
liver and through the spleen (9). It has also been found that nanoparticles of size 40 to 
50nm have a maximum uptake rate  in vitro  (10) while for in vivo studies the optimum size 
range is between 10 to 100nm (11). The effect of size in the cellular uptake was studied 
by Senior et al., who reported that liposomes with size greater than 400nm, were removed 
faster (0.2h) towards the liver than small vesicles, 200nm, that stayed more time in 
circulation through the blood stream (1.5h) (12, 13).  
1.2 Shape of nanoparticles 
The internalization and interaction of the nanoparticles is also very dependent on the 
shape that the nanoparticle acquires. Different shapes will generate different 
hydrodynamic forces and different motion through the vasculature and lead to specific 
trajectories (8). The symmetry of the particles will dictate if they are more effectively taken 
up, by accommodating better to the cellular membrane. Spherical particles have constant 
forces acting on themselves allowing the flow to happen without major interferences (14). 
However, asymmetrical particles, because of their shape, are subjected to different forces 
acting on them as well as resulting in considerable changes of trajectory relative to the 
main flow, ending up accumulating in the blood vessels walls (15). The circulation time 
also varies with the shape of the particles such as spherical particles that are cleared 
more rapidly than asymmetrical ones (14). 
1.3 Surface charge of nanoparticles 
Particles charge is important when considering their binding capacity towards the target 
site. The non-specific binding during the circulation is one of the factors that leads to poor 
bioavailability and to low efficiency rate. Positively charged nanoparticles will bind to 
anionic nucleic acids, proteins, glycans and phospholipids based groups situated on the 
cell surface, enhancing the cellular uptake due to the higher cellular binding (16). 
Negatively charged particles are taken up more efficiently than neutral particles (17). The 
clearance pathway will also be affected by the charge of the particles, positively charged 
particles will be cleared via the mononuclear phagocyte system and subsequently be 
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cleared more rapidly due to interactions with blood proteins, activating the complement 
pathway (8).  
1.4 Hydrophobic/hydrophilic character of nanoparticles  
Nanoparticles that are more hydrophobic than the cell surface will enhance the uptake 
and the amount of proteins linked to their surface (16). This characteristic will lead to more 
rapid clearing than hydrophilic particles that don’t have the same amount of proteins 
binding to their surface and thus remain more time in circulation (8). It is now well known 
that polymers like polyethylene glycol (PEG) offer a hydrophilic surface to the particles, 
avoiding protein adsorption and delaying the clearance of the carriers (4).  
1.5 Mechanical flexibility of nanoparticles 
Flexible particles spend more time in circulation than rigid ones that can potentially clog 
the vessels if they are not small enough (4). These rigid particles were shown to be taken 
up by macrophages contrary to the soft particles that are not so susceptible of being 
adsorbed by these cells (18).    
There are many factors that affect the design and final performance of nanocarriers, 
potentiating different interactions and making it impossible to predict every reaction and 
every factor that will be influenced in a determined system. It is of extreme importance to 
study these factors and to try experimentally to find answers for these nanoparticle 
systems. 
1.6 Types of nanoparticles 
In recent years, several nanocarriers have been developed with a wide range of 
characteristics as can be seen in Figure 1. In the following subsections, some of the most 
common nanoparticles used for drug delivery applications are described. 
 
Figure 1. Some types of nanoparticles used for drug delivery: (a) liposome; (b) dendrimer; (c) 
functionalized polymer; (d) micelle. Adapted from Cole et al. 2015 
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1.6.1 Carbon-based nanocarriers 
Carbon-based nanocarriers such as fullerenes, carbon dots, nanodiamonds and 
nanofoams are being investigated as a promising area of nanoparticles research and 
specially carbon nanotubes that are being suggested as drug carriers (5). These hollow 
cylinders are composed of rolled sheets of graphene and exhibit single or multi-walled 
morphology (19). They have unique structures and a specific combination of 
characteristics (mechanical, thermal, surface, optical, magnetic, electrical, chemical) that 
turns them ideal for in vivo drug delivery applications. Being flexible, they are able to 
penetrate cells and tissues. Regarding biocompability, it has been reported that they 
activate the complement system through classical and alternate pathways, inducing  
inflammation, oxidative stress, apoptosis, toxicity, lipid peroxidation, mitochondrial 
dysfunction, changes in cell morphology and platelet aggregation (20). For these reasons, 
the study of their toxicity is tremendously important and should be addressed with high 
priority. It has been concluded that it is necessary to make material modifications to fully 
avail the benefits of the carbon nanotubes-based biomaterials (21). 
In recent years, Graphene Oxide (GO) has become a potential candidate for drug delivery 
applications. Graphene is a single layer sheet structure that naturally exists as graphite in 
bulk form (5). Modified GO has been used for targeted drug delivery and controlled 
release in tumor therapy (22). The effect of GO on cells revealed no cytotoxicity (23) even 
though it can cause oxidative stress and loss of cell viability depending on the size and 
concentrations used.  
It is still needed to further study the biocompability of these nanoparticles prior to their use 
in clinical settings and find a compromise between the effective delivery of drugs and the 
systemic toxicity caused. 
1.6.2 Dendrimers 
 Dendrimers are spherical branched structures composed of a core molecule and 
polymeric tree-like extensions that allow physical entrapment or encapsulation of 
pharmaceuticals (24). Their synthesis allows easy purification and a great control on the 
final characteristics. They are the smallest nanoparticle system, ranging between 2.5 to 8 
nm (24). Dendrimers can have therapeutics attached to their branches via the functional 
groups, incorporated in the channels formed throughout the molecule or encapsulated in 
their core in case of an hydrophobic drug (25). In addition to drug encapsulation 
advantages, I-labelled anionic PAMAMs of lower generation also enhance the cellular 
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permeability improving oral drug delivery (26). Dendrimers can even act as natural 
antitumor, antiviral and antibacterial agents (27).  
1.6.3 Lipid-based nanocarriers 
Lipid based nanocarriers have also gain great attention for the drug delivery applications 
in recent years. Liposomes, one of the most used lipid-based nanocarriers, are generally 
composed of one or more bilayers of an aliphatic lipid molecule that forms a vesicle (5). 
These structures allow encapsulation of pharmaceutics inside the vesicle, entrapped by its 
layers. The advantages of these nanocarriers are easy functionalization, tunable surface 
properties and controlled size for specific drug delivery system (28). Liposomes are also 
known for activating the immune system, especially those with a positive surface charge 
(29). One of the downsides of liposomes is their selectivity with functionally compatible 
drugs, since the particles are unable to release sufficient amount of drug to be efficient as 
an antitumor agent, even after passive accumulation at tumor sites (5).  
Other type of lipid-based nanocarriers are solid lipid nanoparticles (SLN). SLN are 
“colloidal particles of highly purified triglycerides, complex glyceride mixtures, or waxes 
stabilized by a surfactant” (30). They are produced by changing the oil phase of a oil/water 
emulsion for a solid lipid, allowing them to remain solid at room and body temperature 
(31). SLN are very popular as colloidal carriers because they allow controlled drug release 
and drug targeting, increasing the drug stability without inducing toxicity. In the designing 
of SLN, organic solvents can be avoided, and incorporation of lipophilic and hydrophilic 
drugs are enhanced (31). On the other hand, the disadvantages associated with SLN are 
the low drug loading and the polymorphic transition, which can lead to the expulsion of the 
drug from the carrier during the shelf-life of these systems (32).   
Lipid-based nanocarriers are vulnerable to changes in temperature and osmotic pressure, 
being unstable in biological media, thus suggesting the need to use stable enhancing 
alterations (25). 
1.7 Polymer based nanocarriers  
Polymeric nanoparticles are comprised of a wide range of synthetic polymers, natural 
polymers and pseudosynthetic polymers (5). These nanoparticles are used as drug 
carriers thanks to their architecture, composition, stability and solubility (33). They have 
been described as excellent carriers because of their ability to provide protection to the 
drug, being able to release the encapsulated drugs in a controlled way and targeting them 
with a capacity for accumulation in the tumor site (33). Another advantage of these 
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nanoparticles is their ability to overcome poor solubility of some drugs and enhanced their 
biodistribution (34). These nanoparticles can take the shape of nanospheres or 
nanocapsules, on the first the drug is dispersed in the particle, while in the latter case, it is 
entrapped inside the vesicle and surrounded by a polymeric membrane (35). This 
nanocarriers system also allows the use of hydrophilic and hydrophobic drugs, attaching 
them to the nanoparticle’s surface or encapsulating it inside their core.  
The biodegradable polymers mostly used are poly(lactic-co-glycolic acid) PLGA, polylactic 
acid (PLA), poly-ε-caprolactone (PCL), poly-alkyl-cyanoacrylates (PAC) and chitosan (4). 
PLA is a biocompatible and biodegradable polymer that is easily eliminated from the 
organism once it suffers scission into monomeric units of lactic acid (4). Xing et al. 
reported that oridonin PLA entrapped nanoparticles enhanced the solubility and extend 
the blood circulation time of this diterpenoid that induces cytotoxicity to a wide variety of 
cancer cells (36, 37). 
PLC is particularly interesting for the preparation of long-term implantable devices thanks 
to its longer degradation time, comparing to polylactide (4). Several anticancer drug 
molecules used for cancer treatment had been studied by incorporation into PCL aiming 
to improve the therapeutic index of these molecules (38, 39). 
PAC is a biodegradable and biocompatible polymer and when preparing the PAC 
nanoparticles several methods such as emulsion polymerization, interfacial polymerization 
and nanoprecipitation have been used for the preparation of PAC nanoparticles (40). The 
encapsulation of various antibacterials (ampicillin), anti-inflammatory (indomethacin) and 
anticancer drugs (doxorubicin and ftorafur) has been used for delivery using PAC 
nanoparticles which have shown the polymer to be a strong candidate for future 
investigations as a drug release vehicle (40).   
Derived from the crustacean, natural biopolymer chitin, chitosan is a modified 
carbohydrate polymer that has successfully encapsulated several molecules for in vivo 
purposes (40). Chitosan nanoparticles have served as matrixes of a range of drugs from 
antihormonal (glycyrrhizin) to insulin, where the intestinal absorption following oral 
administration was enhanced; chitosan nanoparticles have also showed great results 
regarding drugs delivery to the ocular surface (40). De Campos et al. showed that 
chitosan NPs loaded with cyclosporin A can contact directly with corneal and conjunctiva 
surfaces, where the delivery is more effective and the inner ocular structures are not 
compromised, as well as, the systemic drug exposure is reduced (41).  
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1.7.1 Poly (lactic-co-glycolic acid) nanoparticles 
Poly (lactic-co-glycolic acid) (PLGA) is a co-polymer widely used for drug delivery 
applications. The hydrolysis products of PLGA leads to form lactic acid and glycolic acid, 
which are metabolites, thus being considered a biodegradable and biocompatible polymer 
(42). The degradation time can vary according to the ratios of each monomer and 
molecular weight (43). These nanoparticles are believed to enter the cells by fluid phase 
pinocytosis and also through clathrin-mediated endocytosis, rapidly entering the 
cytoplasm escaping from the endo-lysosomes (43).   
1.7.1.1 Methods of formulation of PLGA 
These nanoparticles can be prepared by different methods, resulting in various structures 
and drug loading capacities. The drug can be encapsulated inside a core of a 
“nanocapsule” or entrapped or adsorbed in a matrix structure of a “nanosphere”. 
Regarding PLGA nanoparticles, the most common technique is emulsification-solvent 
evaporation technique, where the polymer and the compound are dissolved in an organic 
solvent and then water and a surfactant are added to the polymer solution to form an 
oil/water emulsion. The nanosized droplets are formed by sonication or homogenization, 
the solvent is evaporated or extracted from the solution and the nanoparticles are 
collected after centrifugation (43). This method was recently altered to achieve a double 
water/oil/water emulsion (W/O/W) where it is possible to encapsulate hydrophilic drugs 
(peptides, proteins and nucleic acids). 
Another technique used is the nanoprecipitation method/interfacial deposition method 
when the polymer and drug are dissolved in an organic solvent and then added dropwise 
to water, letting the organic solvent to evaporate and collecting the nanoparticles after 
centrifugation (44).  
The spray-drying method is also becoming a popular method for the formulation of PLGA 
nanoparticles (45). 
Drug loading can occur in two different phases of their production: incorporation of the 
drug during the nanoparticles (NPs) production or adsorption of the drug after the NPs 
production (43). 
1.7.1.2 Physico-chemical properties of PLGA 
PLGA NPs are often surface modified since the natural charge of PLGA NPs is negative 
and it has been shown that particles with cationic surface charge are easier to entering 
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through the cells (43). To assess the particle charge, the most common measurement 
performed is the zeta-potencial where the mobility of charged particles is monitored by an 
electrical potential. This measurement can be made using dynamic light scattering, where 
the Brownian motion of the particles causes dispersion of light and makes it possible to 
measure these fluctuations (46). The particles size and polydispersity index can also be 
measured using this technique. Other imaging techniques such as scanning or 
transmission electron microscopy or atomic force microscopy can also provide this 
information about the particles. The typical size of these particles is between 100 to 250 
nm (43).  
1.7.1.3 Encapsulation of small hydrophobic drugs in PLGA 
Generally, the method used to incorporate hydrophobic poorly soluble drugs into PLGA 
NPs is by nanoprecipitation. To guarantee the drug release and the effective response of 
the NPs, several parameters are influential for the optimal performance, including surface 
modifications, the preparation method, particle size, the drug’s molecular weight and the 
ratio of lactide to glycolide moieties used (40). PLGA NPs have been described as 
efficient nanocarriers for different anti-cancer agents such as paclitaxel (47), 9-
nitrocamptothecin (48), cisplatin (49), and others, and even for several other drugs as 
haloperidol (50), estradiol (51), etc. 
1.7.1.4 Encapsulation of proteins in PLGA 
The oral bioavailability of proteins is very limited, since it is difficult for them to overpass 
the epithelial barriers of the gastro-intestinal tract (GIT), they are degraded by digestive 
enzymes, present a short half-life in vivo and difficulty in diffusion across some biological 
barriers (43). Encapsulating proteins inside PLGA NPs can be a promising solution for 
some of the above mentioned challenges. Encapsulation of proteins enables their 
protection against enzymatic and hydrolytic degradation, maintains their integrity and 
therefore, their activity, while their bioavailability could be improved (43). However, there 
are some problems that can occur during the nanoparticles preparation. The most utilized 
method for the encapsulation of proteins inside PLGA NPs is the double emulsion W/O/W 
solvent evaporation method since proteins are normally hydrophilic macromolecules. 
During this method, the proteins can be dissolved in the aqueous phase but can 
aggregate or denature at the water/organic solvent interface. They can also be adsorbed 
to the hydrophobic polymer or unfold because of the shear stress used during the method. 
If this happens, denatured or aggregated proteins can cause side effects like toxicity or 
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immunogenicity and induce the opposite reactions (52). For this reason, the protein 
stability is extremely important and is being studied for its improvement. 
Another problem regarding protein stability is the exposure to an acidic environment, 
caused by the degradation products (lactic acid and glycolic acid) and by the carboxylic 
acid end groups that can interact with the positive charges of the encapsulated protein. 
This interaction can alter or block its release from the NP. The acidic pH can also lead to 
aggregation of the protein or affect its activity (53). Stabilizing agents such as pluranic 
F68, trehalose and sodium bicarbonate can increase the protein stability and are 
important tools to optimize this procedure (54). 
1.7.1.3 Encapsulation of nucleic acids in PLGA 
Nucleic acids are fragile, have a large size and are negatively charged leading to poor 
intrinsic transfection efficiency. In therapeutics, nucleic acids can promote gene 
expression by delivering a gene that is not present or not expressed (cDNA) or by 
silencing the expression of determined genes (RNAi mediators). The nucleic acids can be 
entrapped into the polymeric matrix or adsorbed by electrostatic interaction on the 
nanoparticle surface by adding surfactants or cationic polymers to it (55, 56). The W/O/W 
solvent evaporation method and the modified nanoprecipitation methods are used for the 
encapsulation of nucleic acids and there aren’t visible major differences regarding the two 
methods used. By adding cationic polymers as polyethylenimine (PEI) (57) or chitosan 
(58), the encapsulation efficiency is augmented and the cellular uptake and endosomal 
escape are enhanced. Still, even with high encapsulation efficiency, the nucleic acid 
loading remains relatively low (0.1 to 1 mg per 100 mg of NPs) (43). 
1.8 Metallic nanoparticles 
Metallic nanoparticles have potential to be used as targeted drug delivery vehicles but 
also as imaging agents thanks to their unique physical and chemical properties that 
include plasmonic resonance and fluorescence enhancement as well as catalytic activity 
enhancement (59). The most used metals to form metallic nanoparticles are Iron, Zinc, 
Gold and Silver. These nanoparticles can carry large drugs doses and increase their 
circulatory half-life since they have a large surface area and area to volume ratio (59). 
Metallic nanoparticles have the ability to produce Reactive Oxygen Species (ROS) and 
this characteristic can be used to kill cancer cells (60). Regarding imaging abilities, their 
photoluminescence and superparamagnetic properties turns them into potential 
candidates for monitoring cancer treatment (61). Depending on the metal used, size and 
shape of the nanoparticle and its surface properties, there are several processes 
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described as potential procedures to kill cancer cells: hyperthermia, photothermal effect 
and ROS generation (59). 
The synthesis processes used to form metallic nanoparticles vary from reduction, 
sonolysis, hydrothermal synthesis and pyrolysis (59). The size and shape will vary 
depending on the method used during their production, the best one should be considered 
depending on the final goal. 
1.8.1 Gold nanoparticles 
Gold nanoparticles (AuNPs) have unique physicochemical properties that distinguish 
them, their chemical inertness, facile surface functionalization, surface plasmon 
resonance and optical properties all of which turns them great candidates for drug delivery 
and imaging agents (62). AuNPs can be processed in to a wide range of sizes and shapes 
making them interesting for different approaches. 
Hyperthermia can be induced by AuNPs, when radiation of near infrared (NIR) light is 
focused on these particles and because of its optical properties offers  photothermal 
therapy for cancer therapy (62).  
1.8.1.1 Synthesis methods of AuNPs 
There are different synthesis methods for obtaining gold nanoparticles. Some of the most 
common methods are: 
 Turkevich method (63) – reduction of Au3+ to neutral Au atoms using hot 
chloroauric acid reacting with sodium citrate. Gold starts to precipitate in the form 
of nanoparticles from the supersaturated solution 
 Perrault method (64) – chloroauric acid is reduced by hydroquinone, which 
improves the monodispersity and shape consistency due to its weak reducing 
potential 
 Block copolymer-mediated synthesis (65) – Au ions are reduced by block 
copolymers forming clusters whose surfaces are then reduced to grow the 
nanoparticle that are later stabilized  
 Brust method (66) – Chloroauric acid reacts with tetraoctylammonium bromide 
(TOAB) that is a phase-transfer catalyst and stabilizing agent and with sodium 
borohydride that acts as reducing agent 
Each method has different advantages and disadvantages and should be used depending 
on the final objective. 
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1.8.1.2 Therapeutic applications of AuNPs 
Plasmonic gold nanoparticles can attach themselves to cancer cells via molecular 
targeting and delivered to tumor sites via the enhanced permeability and retention (EPR) 
effect (67). On accumulating at the tumor site, they can be triggered by external radiation 
and cause hyperthermia, leading to apoptosis. Another advantage of these particles is 
that they can be triggered by NIR light that passes easily through the epithelial tissue and 
causes minimal interference with water and hemoglobin (68). 
The nanometer size and EPR within tumor site, allied to the facility to functionalize the 
surface chemistry of these nanoparticles with different biomolecules, turn them into ideal 
drug delivery candidates. Their ability to bind to drug molecules also enhances the drug 
efficiency and efficacy rate. The combination of all these characteristics, allows controlled 
drug release internally or externally, by biological stimuli or light activation (69). Therefore, 
AuNPs are undoubtedly excellent platforms for effective drug delivery. 
There is another area where gold nanoparticles can offer a promising alternative, as 
nonviral gene delivery agents. By helping circumvent some of the barriers like cell 
membrane penetration, enzymatic degradation and the effective delivery of the gene to 
the nucleus, they can be a useful tool for gene regulation (69). Attaching DNA molecules 
to AuNPs may allow the knockdown of a gene of interest (70). Conjugating them with 
small interference RNA (siRNA) and exposing them to internal or external stimuli, the 
siRNA can be released and the RNA interference (RNAi) activity will increase, interfering 
with normal gene function (69). 
1.9 Multifunctional nanoparticles 
The development of “multifunctional” nanoparticles seeks to enhance benefits brought by 
nanoparticles combining different functionalities as improved delivery, imaging properties, 
targeting and therapeutic outcome (71). These nanoparticles offer a broad range of 
benefits and can overcome several challenges towards the improvement of the 
therapeutic index of the drugs used. The advantages of multifunctional nanoparticles 
include evading the immune system and preventing opsonization, preventing degradation 
of the protective cargo, targeting specificity, improved cell uptake and controlled drug 
release (71).   
By combining therapeutic and diagnostic functions in a single nanoparticle, theranostic 
agents are formed, which can simultaneously deliver imaging and therapeutic benefits to 
specific sites or organs, allowing the detection and treatment of a disease to occur in a 
single procedure (72).  
Introduction  
 
12 
 
Ideal theranostic agents must accumulate rapidly and selectively, reporting biochemical 
and morphologic characteristics of the disease while efficiently delivering the drug that 
must be cleared rapidly from the body or be biodegraded into nontoxic byproducts that are 
safe for Humans (72). This is a trend to personalize disease management and to improve 
the efficacy lowering the toxicity and thus increasing the quality of life and patient 
outcome.  
 
Figure 2. Scheme of a theranostic nanoparticle. Adapted from Cole et al. 2015 
Although theranostic nanoparticles bring a lot of positive aspects, there are also some 
challenges that must be faced when considering these nanoparticles. By adding an 
imaging agent to a drug carrier, some imaging properties might be acquired but can be 
still below the threshold for images with sufficient quality and resolution. Another 
drawback might be the low drug loading capacity of nanoparticle-based imaging agents 
that only allow a small number of drug molecules to be incorporated per particle. For 
therapeutic purposes, a long circulation time is preferred to enhance tumor accumulation 
via EPR, but for imaging purposes, the contrast agent must be cleared rapidly to 
accurately evaluate the images of the site of interest. Therefore, a compromise between 
optimal features of both factors must be achieved, considering the increasing costs and 
complexity of synthesis and purification steps when adding more features to the particles, 
forming more heterogeneous formulations (71). The response for this challenge might be 
the use of nanomaterials that exhibit an intrinsic utility for both imaging and therapy. Some 
examples include iron oxide nanoparticles, which are ideal both for MR imaging and 
thermal ablation therapy (73), gold nanoparticles for computer tomography (CT), imaging 
and radiation therapy (74) and even for CT imaging and thermal ablation therapy (74). 
These nanoparticles, when irradiated with the appropriate form of energy, absorb the 
incident energy and convert it to heat, which kills the cancerous cells (71). The most 
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common energy sources used are near infrared light, radiowaves or an alternating 
magnetic field (71). 
Still, at the moment, the overall point of view considers that addition of targeting ligands to 
therapeutic nanoparticles is worth the additional complexity of synthesis, cost and 
regulations (71).  
1.10 Stimuli-responsive nanocarriers 
The nanotechnology-based targeted delivery is evolving rapidly, aiming to overcome the 
difficulties to control the release of the drug from the targeting nanocarrier. A solution 
seems to possibly be on-demand processes (also known as “switch on/off”) that allow 
tailored-release profiles with excellent temporal, spatial and dosage control (75). When 
designing the stimuli-responsive systems, the microenvironment of the release should be 
recognized by the nanocarrier and it should act in a dynamic way, mimicking the organism 
behavior. The materials used should be biocompatible and have specific characteristics 
that enables it to undergo specific protonation, hydrolytic cleavage and molecular or 
supremolecular conformational change when responding to a specific stimuli, or being 
susceptible to specific physical stimulation (75). 
Nanodelivery systems may be susceptible to different types of stimuli, being exogenous or 
endogenous. As exogenous stimuli, there are thermoresponsive systems, magnetically 
responsive systems, ultrasound-triggered drug delivery, light-triggered drug delivery and 
electroresponsive systems. Regarding endogenous stimuli, there are different approaches 
under study, some of them include pH-sensitive systems, redox-sensitive systems, 
enzyme-sensitive systems and self-regulated systems (75). 
The wide range of stimuli that can trigger the drug release from a nanocarrier at the right 
time and place allows great flexibility and diverse responses to problems regarding the 
release of the therapeutic. Although the complexity of their designing and synthesis 
makes it difficult to scale up and transfer the technology from the laboratories to their 
mass use, the developments made in this field of research offer a great potential.  
1.11 Scope and aims 
The potential of this field to improve the current state of pharmaceutics is enormous and 
the interest to explore is big. 
Following this thought, the development of nanocarriers that can offer multiple advantages 
and a wide range of solutions for drug delivery and imaging properties is interesting and 
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provides challenges and great benefits if well accomplished. Therefore, the aim of this 
thesis was to design a nanocarrier capable of transporting a therapeutic agent while 
providing imaging information regarding the environment of the cancer site.  
PLGA nanoparticles and AuNPs were developed with the aim to form a multiple functional 
nanoparticle, capable of therapeutic effect by transferring light triggered to heat, offering 
targeted treatment. The nanoparticles were developed and their toxicity, transfection and 
microscopy assays were performed in order to evaluate the nanoparticles’ characteristics 
and evaluate their therapeutic potential.  
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2. Materials and Methods 
2.1 Buffers 
2.1.1 Hepes buffer 
Hepes buffer solution of 20 mM concentration at pH 7.2 was made by dissolving 1.19 g 
Hepes (Sigma-Aldrich, USA) in 250 mL of deionized water.  
2.1.2 TBE buffer 
TBE buffer was made with 10.8 g of Tris base (Sigma-Aldrich, USA), 5.5 g boric acid 
(VWR International, USA) and 4 mL of EDTA pH 8.0 (Merck, Germany) dissolved in 1 L of 
deionized water.  
2.1.3 Flow buffer 
This is a buffer used for samples ready to analyse with flow cytometry. Sodium azide used 
to prevent microbial growth and fix the cells (inhibit their energy dependent activities). 
Flow buffer was made adding 0.1% Sodium azide (Sigma-Aldrich, USA) and 1.0% Bovine 
Serum Albumin (BSA) (Sigma-Aldrich, USA) to 500 mL of Phosphate-buffered saline 
(PBS) (Gibco, VS). 
2.2 Chemicals 
The chemicals chloroauric acid (HAuCl4), sodium citrate (C6H5Na3O7), sodium borohydride 
(NaBH4), PLGA, (N-3-Dimethylaminopropyl-N-ethylcarbodiimide hydrochloride) EDC, (N-
Hydroxysulfosuccinimide sodium salt) NHS, chitosan, protamine sulfate salt, isopropanol, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Trypan Blue were 
all purchased from Sigma-Aldrich, USA. 
The Dulbecco’s modified Eagle’s medium (DMEM) and agarose were obtained from 
Invitrogen, LifeTechnologies (Carlsbad, USA). The acetone was obtained from Fisher 
Chemical and the sodium chloride (NaCl), yeast extract and tryptone from International 
Medical. OptiMEM reduced serum medium was purchased from Gibco,VS. 
QIAGEN QIAfilter Gigakit was obtained from Qiagen®, Venlo, The Netherlands. The 
plasmid constructs gWIZ-GFP (Promega, Leiden, The Netherlands) were amplified in 
transformed E. coli bacteria. Alexa647-siRNA was purchased from Eurogentec, Seraing, 
Belgium. 
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2.3 Equipments  
 Flow cytometer FACS Calibur, BD Biosciences Benelux N.V., Erembodegem, 
Belgium 
 Microscope Nikon TE200E, NIKON BELUX, Brussels, Belgium 
 Confocal laser scanning microscope, MRC1024 UV, Bio-Rad, Hemel Hempstead, 
UK 
 Plate spectrophotometer Perkin Elmer 2104 Envision 
 Ultracentrifuge, Beckman Coulter 
 UV-Vis spectrophotometer Nanodrop 2000 C Spectrophotometer, Thermo Fisher 
Scientific, Rockford, IL, USA 
 Zetasizer Nano Series, Malvern Instruments, Hoeilaart, Belgium 
2.4 Preparation of gold nanoparticles (AuNPs) 
The AuNPs were prepared using different reducing agents, concentrations and 
temperature conditions. The nanoparticles that were considered promising and showed 
reproducibility and stability over time are described. 
2.4.1 Preparation of AuNPs using sodium citrate as reducing agent 
Sodium citrate is known as an effective reducing agent and is widely used for the 
preparation of gold nanoparticles (63). The synthesis reaction was performed using 1 mL 
of HAuCl4 solution of 1 mg/mL and 1 mL of MiliQ Water to which 1 mL of Sodium citrate 
solution of 1 mg/mL was added. The solution was stirring at 200 rpm (VWR VS-C4, USA) 
for 5 min at room temperature.  
   +  
Figure 3. Structural formula of HAuCl4 and Sodium citrate 
The same experiment was performed with the solution at 90°C and stirring at 500 rpm 
(IKA® RCT basic) for 5 min. 
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2.4.2 Preparation of AuNPs using sodium citrate and sodium borohydride 
NaBH4 is an inorganic compound used as reducing agent for several reactions. It has also 
been used to synthesize gold nanoparticles reducing HAuCl4. Both the reducing agents 
were used with the aim to obtain reproducible and stable gold nanoparticles. Both ratios of 
reagents and temperature conditions were also varied. 
2.5 Preparation of PLGA – poly(lactic-co-glycolic acid) Nanoparticles 
2.5.1 Preparation of PLGA NPs 
The PLGA NPs were prepared adding 40 mg of PLGA to 5 mL of acetone. This solution 
was stirred for 20 min at 200 rpm (VWR VS-C4, USA). After 20 min, the PLGA solution 
was added dropwise to 20 mL of MiliQ Water using a syringe and needle (Figure 4). This 
solution was stirred at 500 rpm for 10 min and kept overnight to remove acetone by 
evaporation.  
 
Figure 4. Addition of the PLGA solution dropwise to water, forming the nanoparticles 
  
2.5.2 Preparation of PLGA NPs conjugated with chitosan and protamine 
The positively charged NPs were made using the 8 mg/mL PLGA NPs described in 2.3.1 
and adding 0.5 mM of EDC (N-3-Dimethylaminopropyl-N-ethylcarbodiimide hydro-
chloride) and 0.25 mM of NHS (N-Hydroxysulfosuccinimide sodium salt). The chitosan 
and protamine were conjugated to the PLGA NPs by using carbodiimide chemistry 
(NHS/EDC)  (76). Briefly, the PLGA NPs were activated by EDC/NHS and added 
dropwise to a solution of 1 mg/mL of Chitosan or Protamine. They were allowed to stay at 
room temperature stirring for 20 min. The modified PLGA based nanoparticles were 
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centrifuged at 10 000 rpm for 15 min at 15°C using an Ultracentrifuge (Beckman Coulter) 
to eliminate unreacted chitosan or protamine. 
2.5.3 Preparation of PLGA NPs with Quantum Dots (QDs) 
The QDs used were FL59: flash CdSe/CdS core-shell QDs with size of 13.4 nm and 
quantum yield of 70%. They have been previously prepared and for this study an aliquot 
of the QDs solution was used (77). 
The PLGA NPs with QDs were prepared by mixing 20 mg of PLGA in 2.5 mL of acetone 
with different amounts of QDs (2, 4, 6, 8, 10, 20, 30, 40 and 50 µL). This solution was 
stirred for 20 min at 200 rpm (VWR VS-C4, USA) and was subsequently added to 10 mL 
of MiliQ Water. For the preparation of the positively charged PLGA NPs with QDs, the 
same procedure as described in 2.4.2 was followed.  
2.6 Dynamic light scattering (DLS) of the NPs  
Dynamic light scattering (DLS), a non-invasive technique, was employed to characterize 
the size and surface charge of the particles by measuring the hydrodynamic diameter, 
polydispersity index (PDI) and zeta-potential using a Zetasizer Nano Series (Malvern 
Instruments, Hoeilaart, Belgium). The particles suspensions were added into the 
disposable folded capillary cell DTS 1070. Measurements were carried out at temperature 
of 25°C and scattering angle 173°. All samples were measured in triplicate.  
2.7 UV-Visible absorption of the NPs suspensions 
Nanoparticles have optical properties that are sensitive to size, shape, concentration, 
agglomeration state and nanoparticle surface, which makes UV-Vis spectroscopy a 
valuable tool for identifying, characterizing, and studying these materials. Gold 
nanoparticles strongly interact with specific wavelengths of light and the unique optical 
properties of these materials are the foundation for the field of plasmonics. 
2.8 Plasmid Purification 
QIAGEN plasmid purification protocols are based on a modified alkaline lysis procedure, 
followed by the binding of the plasmid with QIAGEN Anion-Exchange Resin, with low-salt 
and appropriate pH conditions. All the non-desired molecules (RNA, proteins, dyes and 
low-molecular-weight impurities) are removed when the medium-salt wash is performed. 
The plasmid DNA is eluted in a high-salt buffer and by isopropanol precipitation it is 
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concentrated and desalted. Each disposable QIAGEN-tip packed with QIAGEN Resin 
should be used by gravity flow.  
The plasmid multiplication in bacteria occurs when 1 or 2 bacteria beads are added to 
falcon tubes (Corning Incorporated) containing Lysogeny Broth (LB) medium (10 g of 
NaCl, 5 g of Yeast extract, 10 g of Tryptone diluted in distilled water to 1 L) with Ampicilin 
and are incubated at 37°C for 8 h at 250 rpm (New Brunswick Scientific). After 8 h of 
incubation, the bacteria culture is transferred to an Erlenmeyer with 800 mL of LB medium 
and incubated again at 37°C and 300 rpm for 12-16 h. On the day after, the bacteria 
suspension is transferred to centrifuge flaks (Corning Incorporated) and centrifuged for 15 
min at 4°C at 6000 g. 
The bacteria lysis is made by ressuspending the pellets in 125 mL of P1 buffer, then 
transferring it to Schot bottles and adding 125 mL of P2 buffer, incubating for 5 min for the 
cells to lyse, adding then 125 mL of P3 buffer and mixing gently. The lysate clearance is 
made using the QIAfilter cartridge with a QIAGEN tip and QBT buffer by gravity flow.  
After the filtered lysate is poured in the QIAGEN tip, the ion exchange chromatography is 
performed washing the tip with QC buffer and then eluting the pDNA from the QIAGEN tip 
with QF buffer. 
The precipitation and washing of the pDNA occurs when the eluted pDNA is divided to 
small centrifuge tubes with 0.3 volumes of isopropanol and incubated for 1 h at -20°C, 
being subsequently centrifuged for 30 min at 14 600 g at 4°C. The pellet is washed with 5 
mL of ice cold 70% EtOH, centrifuged for 10 min at 15 000 g and 4°C and then air-dried at 
-20°C for 2-5 min. The pellet is then ressuspended with 500 µL of HEPES, transferred to 
eppendorf and stored at -20°C. 
2.9 Gel Electrophoresis of the nanoparticles complexed with pDNA 
Lipoplexes corresponding to 50 ng pDNA were prepared as previously described, after 
which 5 µL of Ambion loading buffer (Ambion, Merelbeke, Belgium) was added to the 
suspension. The mixture was loaded on a 1% agarose gel in 1 x TBE buffer, to which 
GelRed (Biotium, Hayward, CA) was added for visualization of the pDNA. The gel was run 
for 40 min at 100 V and imaged. 
2.9.1 Complexation of the cationic nanoparticles with pDNA 
The complexation between pDNA and cationic NPs occurs via electrostatic interaction, the 
negatively charged nucleic acid forms an electrostatic bond with the positively charged 
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NPs. The study of the complexation potential is interesting to evaluate the efficiency of the 
NPs to be used as gene therapy carriers.  
The complexes were made using different volumes of nanoparticles represented in Table 
1, which correspond to the concentrations displaced in Table 2. The concentration of 
pDNA was kept constant (1 µg/µL) for all the samples. The complexes were allowed to 
stay at room temperature for 20 min before being transferred to the gel electrophoresis.  
 
Table 1. Complexation volumes used for gel electrophoresis 
NPs volume 
(µL) 
Hepes buffer 
(µL) 
pDNA 
(µL) 
Loading buffer 
(µL) 
Total volume 
(µL) 
1 18 1 5 25 
5 14 1 5 25 
10 9 1 5 25 
15 4 1 5 25 
17 2 1 5 25 
19 0 1 5 25 
 
Table 2. Complexation concentrations used for gel electrophoresis 
Chitosan coated 
PLGA NPs 
(mg/mL) 
Protamine coated 
PLGA NPs (mg/mL) 
Chitosan coated 
PLGA QDs NPs 
(mg/mL) 
Protamine coated 
PLGA QDs NPs 
(mg/mL) 
0.4 0.9 0.1 0.2 
0.8 1.8 0.6 0.8 
1.6 3.6 0.8 1.2 
2.4 5.4 1 2 
3.2 7.2 - - 
4 9 - - 
 
2.10 Cell culture for cytotoxicity and transfection evaluation 
The experiments to evaluate cytotoxicity and transfection efficiency were performed with 
HeLa cells, a human cervix carcinoma cell line. These cancer cells were the first 
immortalized human cell line to be grown in tissue culture and are derived from cervical 
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cancer cells from Henrietta Lacks, a patient suffering from this cancer (78). These cells 
are able to grow and adhere at plastic surfaces, becoming easily attached to culture 
flasks, allowing their use and easy maintenance. The materials used for cell culture 
experiments are from Invitrogen, Life Technologies (Carlsbad, USA), unless stated 
otherwise. 
The cell culture medium used during the experiments was Dulbecco's Modified Eagle's 
Medium (DMEM) F12 containing 10% Fetal Bovine Serum, 435 mL DMEM F12, 10 mL 
Penicillin/streptomycin (100 IU/mL penicillin & 100 µg/mL streptomycin), 5 mL L-Glutamin 
2 mM. The medium was filtered (Corning Incorporated, USA) using a vacuum system and 
the cells were incubated in culture flasks (SPL Life Sciences, Korea) at 37°C and 5% CO2. 
For maintaining the cell culture, the cells were trypsinized once they reached a confluency 
of 80-90%. All the medium was removed from the confluent flask and the cells were 
washed once or twice (according to the amount of dead cells) with ~10 mL of PBS. 3 mL 
of Trypsine/EDTA (T/E) at 0,25% was added to the flask and the cells were incubated for 
5 min at 37°C with 5% CO2. After the cells were detached, cell culture medium was added 
to the flask to neutralize the T/E. The cell suspension was transferred to a falcon tube and 
centrifuged at 1100 rpm for 7 min. After centrifugation, the pellet containing the cells was 
ressuspended in new cell culture medium and a certain quantity of this cell suspension 
was transferred to a new flask with culture medium.  
To count the cells for every experiment, after trypsinization, 50 µL of the cell suspension 
was transferred to an eppendorf and 100 µL of Trypan blue was added. From this 
eppendorf, 10 µL were transferred to each side of Bϋrker counting chamber. The cells 
were counted on the microscope and calculations were made afterwards to obtain the 
final number of cells per mL.   
2.11 Cell viability assay: MTT assay 
The cell viability of the NPs was assessed by MTT assay. The MTT is a colorimetric assay 
for accessing cell metabolic activity using the tetrazolium dye MTT 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, which is reduced by NAD(P)H-dependent cellular 
oxidoreductase enzymes to its insoluble formazan, (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-
diphenylformazan (Figure 5).  
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Figure 5. Structures of MTT and colored formazan product. Adapted from Riss et al. 2004 
MTT is a yellow tetrazole reduced to purple formazan in living cells (79). Dimethyl 
sulfoxide (DMSO) is used to dissolve the insoluble purple formazan product into a colored 
solution. To know the absorbance of this colored solution, a spectrophotometer is used 
and the wavelength is chosen (usually between 500 nm and 700 nm). By this 
measurement it is possible to determine the amount of viable cells (79).   
This assay was performed in two days, on day one the HeLa cells were seeded with a 
density of 50 000 cells/well in 24 wells cell plates. Then 5 mg/mL MTT solution was 
prepared in PBS. Different concentrations of NPs were used to observe cytotoxicity. After 
having all the NPs prepared and the cells with an optimal confluence of 50-60%, the cells 
were washed with OptiMEM and 450 µL of OptiMEM was added with 50 µL of particles in 
each well. Following 4 hours of incubation at 37°C and 5% CO2, the OptiMEM and 
particles were removed, the cells were washed again with OptiMEM and then 400 µL of 
fresh culture medium (DMEM F12) was added to each well with 100 µL of MTT reagent. 
The negative control was done by fixating the cells with Paraformaldehyde (PFA) 4% for 
15 min. The cells with the MTT reagent were incubated for 3 hours at 37°C and 5% CO2. 
After 3 hours, the solution was removed and 500 µL of DMSO (Sigma-Aldrich, USA) was 
added to each well. The plates were covered with aluminum foil and placed on an orbital 
shaker for 45 min at 1200 rpm. The UV absorbance at 590 nm and 690 nm was made 
using a plate reader (PerkinElmer 2104 EnVision). 
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2.12 In vitro Transfection of NPs complexed with pDNA 
To assess the transfection efficiency of particles complexed with pDNA, the following 
procedure was performed: 
 The cells were spliced and seeded with a density of 50 000 cells per well. 
 After 24 hours, the complexes were prepared according to the following protocols. 
The pDNA was diluted in HEPES buffer 20 mM pH 7.2 (1µg pDNA per well) and 
then in OptiMEM, and the nanoparticles were diluted to obtain the same 
concentrations tested in the toxicity assay. The nanoparticles were diluted in 
OptiMEM and then mixed with the pDNA and incubated at room temperature for 
20 min. After that, the complexes were added to the cells, 500 µL to each well. 
Incubation occurred for 24 hours at 37°C and 5% CO2, and the culture medium 
was refreshed after 4 hours. A positive control with Lipofectamine TM was used. 
 After 24 hours of incubation, the cells were washed with PBS and trypsinized with 
100 µL of T/E for 5 min at 37°C and 5% CO2 after which 400 µL of cell culture 
medium was added to each well. The cell suspension was centrifuged at 1300 g 
for 6 min. The supernatant was discarded and the pellet dissolved in 300 µL of 
flow buffer. The transfection efficiency was measured on FACS for green 
fluorescence using FACSCalibur and all the data was collected using Cell Quest 
Pro (Beckton Dickinson, Erembodegem, Belgium).  
2.13 Evaluation of NPs diffusion by single particle tracking (SPT) 
The diffusion of NPs was measured using SPT. The NPs were diluted to a suitable 
concentration (108 to 1010 particles/mL) in HEPES buffer (25 mM, pH 7.2). The NPs 
solution of 9µL was applied between a microscope slide and a cover glass with a double-
sided adhesive sticker of 120 µm thickness in between (Secure-Seal Spacer; Molecular 
Probes, Leiden, The Netherlands). The microscope was always focused at 5 to 10 µm 
above the cover glass. For each sample, typically 10 to 20 movies of about 200 frames 
each were recorded at different locations within the sample, at a frame rate of 24 or 35 fps 
depending on the exposure time. All fluorescence video imaging of diffusing nanoparticles 
was performed on a custom-built laser wide field fluorescence microscope setup. Diffusion 
analysis of the videos was performed offline using in-house developed software, providing 
a distribution of apparent diffusion coefficients from which hydrodynamic diameter could 
be calculated. 
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2.14 Evaluation of siRNA release from the NPs by fluorescence correlation 
spectroscopy (FCS) 
siRNA release from the nanoparticles was determined by fluorescence correlation 
spectroscopy. FCS measurements were performed on a MRC1024 Bio-Rad confocal 
laser scanning microscope equipped with a water immersion objective lens (Plan Apo 60X 
NA, 1.2, collar rim correction, Nikon, Japan) and on an LSM510/ConfoCor2 system (Carl 
Zeiss, Jena, Germany), equipped with a type C-Apochromat 40x/1.2 W objective lens. 
The laser beam was focused at about 100 µm above the bottom of a 96-well plate 
(Greiner Bio-one, Frickenhausen, Germany) which contained the samples. 
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3. Results 
3.1 Gold nanoparticles  
3.1.1 Dinamyc Light Scattering (DLS) 
Gold nanoparticles (AuNPs) have attracted much interest in therapeutic research due to 
its physiochemical properties. Many applications of AuNPs depend on three key 
parameters such as size, shape and monodispersity, which can be controlled during 
synthesis process. The citrate caped AuNPs are most commonly used. In the present 
study, we have investigated how the size of the AuNPs varies by concentration of HAuCl4, 
reducing agent and applying co-reducing agent. The size of synthesized AuNPs particle is 
represented in Table 3. The formation of the AuNPs was confirmed by UV spectrum 
shown in Figure 6. The obtain results show that stable AuNPs can be designed at room 
temperature by using co-reducing agent. The AuNPs size can vary by changing the 
concentration of the HAuCl4 and reducing agents. 
 
Table 3. Results of the size measurements of different AuNPs formed in different conditions using 
DLS 
Composition Size (d.nm) PDI 
Temperature 
conditions 
1 mL HAuCl4 + 1 mL H2O 
+ 500 µL Sodium citrate + 
200 µL NaBH4 
41.095 ± 1.3 0.197 
Room 
temperature 
 
1 mL HAuCl4 + 1 mL H2O 
+ 1 mL Sodium citrate + 
100 µL NaBH4 
17.83 ± 5.6 0.199 
Room 
temperature 
1 mL HAuCl4  + 1 mL H2O 
+ 1 mL Sodium citrate + 
50 µL NaBH4 
18.6 ±10.5 0.258 
Room 
temperature 
1 mL HAuCl4 + 1 mL H2O 
+ 500 µL Sodium citrate 
154.35 ± 32.2 0.158 
Room 
temperature 
1 mL HAuCl4 + 1 mL H2O 
+ 500 µL Sodium citrate 
61.875 ± 4.9 0.272 90°C 
 
  
Results  
 
26 
 
3.1.2 UV-Vis absorption of gold nanoparticles 
The UV-Vis absorption spectrum of the solution showed that the absorption peak was 
between 510-540 nm, as expected to confirm the presence of AuNPs in the solution. 
 
 
Figure 6. UV-Vis spectrum of AuNPs reduced with Sodium citrate (a); UV-Vis spectrum of AuNPs 
reduced with Sodium citrate and NaBH4 (b) 
3.2 PLGA nanoparticles 
3.2.1 DLS of PLGA NPs 
The NPs biodistribution and pharmacokinetic properties are largely dependent on their 
size, surface charge and composition. To obtain various sizes of PLGA NPs, different 
concentrations of the PLGA solution was used. The results indicate that the size of PLGA 
NPs increased with increasing the concentration of the PLGA solution (Figure 7). 
 
Figure 7. Sizes of different PLGA NPs with different concentrations of PLGA solution 
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From here onwards we focused only on 175 nm sized particles for further study. The 
centrifugation stability of the PLGA NPs was evaluated by measuring size and surface 
charge before and after centrifugation. 
This new preparation method developed for PLGA NPs showed small variance of size and 
surface charge before and after centrifugation, shown in Figure 4. 
3.2.2 Surface modification of PLGA NPs   
The surface modification of PLGA NPs is a versatile approach to enhance its therapeutic 
applications. In the present study, cationic polymers chitosan and protamine have been 
chosen, for surface modification, which can improve biodistribution and pharmacokinetic 
properties of NPs (80, 81). The carboxylated PLGA NPs were conjugated to the amines of 
chitosan and protamine via carbodiimide chemistry. It was observed that NPs, when 
positively coated increased in size specially upon coating with chitosan in comparison to 
protamine (Figure 8). The coating of chitosan forms a layer on the nanoparticles which 
contributes to the increase in size.  
 
 
Figure 8. Average size of PLGA NPs and PLGA NPs positively coated with Chitosan or Protamine 
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Figure 9. Average Zeta-potencial of PLGA NPs and PLGA NPs positively coated with Chitosan or 
Protamine 
The change of the surface charge of the nanoparticles when coated with chitosan or 
protamine are presented in Figure 9. By comparing the two polymers coatings, it was 
observed that chitosan provides higher positive charge compared to protamine.  
3.3 Evaluation of complexation potential between pDNA and cationic PLGA 
NPs by gel electrophoresis 
The complexation between pDNA and cationic PLGA NPs occurs via electrostatic 
interaction, the negatively charged forms the electrostatic bond with the positively charged 
NPs. The complexation is further evaluated by gel electrophoresis method, where an 
electric field is applied to gel loaded with complexes. The molecules having a negative 
charge migrate towards the positive pole and negatively charged will move towards 
positive pole according to their size. The smaller the molecule, the faster is its migration. 
According to this phenomenon the complexation behavior can be studied. If the pDNA is 
well complexed with cationic PLGA NPs then the migration will be slower or there will be 
no migration at all in comparison to free pDNA which will migrate faster and further. The 
complexation ability of the different concentration of cationic PLGA NPs is shown in Figure 
10 and in Figure 11.  
3.3.1 Complexation potential between pDNA and chitosan coated PLGA NPs  
Gel electrophoresis of pDNA complexed with different concentrations of chitosan coated 
PLGA NPs is shown in Figure 10. The results indicate that the concentration of 2 µg of 
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chitosan coated PLGA NPs doesn’t show good complexation. The NPs concentration 8 µg 
onwards shows good complexation ability.  
 
 
Figure 10. Photo of Gel Electrophoresis of pDNA with PLGA Chitosan NPs 
3.3.2 Complexation potential between pDNA and protamine coated PLGA NPs  
 
Figure 11. Photo of Gel Electrophoresis of pDNA with PLGA Protamine NPs 
The protamine coated cationic PLGA NPs shows complete complexation at NPs 
concentration of 18 µg onwards. 
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3.4 Cytotoxicity evaluation of NPs 
3.4.1 Cytotoxicity of PLGA NPs 
The viability of HeLa cells after being exposed to PLGA NPs is shown in Figure 12. 
Different concentrations were evaluated and the results were compared with the positive 
(Blanc+OptiMEM; Blanc+CCM) and negative (Dead cells) controls. It was observed that 
up to 400 µg of NPs are considered non toxic to the cells. In the present experiment there 
were observed some unexpected result with 40 µg and 265 µg of NPs, which showed 
toxicity, the reason might be some kind of contamination during the procedure. Each 
sample was performed in triplicates and the assay repeated at least three times. The 
Figure 12 shows the average values of all assays.  
 
 
Figure 12. Percentage of viability of HeLa cells after exposure to PLGA NPs 
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3.4.2 Cytotoxicity of chitosan coated PLGA NPs 
The chitosan coated cationic PLGA NPs did not exhibit any toxicity to the HeLa cells after 
exposure with different amounts of NPs. 
 
 
Figure 13. Percentage of viability of HeLa cells after exposure to PLGA Chitosan NPs 
3.4.3 Cytotoxicity of protamine coated PLGA NPs 
The viability of protamine coated cationic PLGA NPs shows toxicity towards HeLa cells. 
This result was unexpected since it has already been reported that low concentration of 
protamine does not show any kind of toxicity (82). 
 
 
Figure 14. Percentage of viability of HeLa cells after exposure to PLGA Protamine NPs 
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3.5 Transfection efficiency of cationic PLGA NPs 
Flow cytometry is a technique which by the use of hydrodynamic focusing creates a 
stream of single cells. The cells pass through a laser beam and light is scattered in 
forward and sideward direction, exciting fluorophores that emit light which is filtered and 
detected. The fluorescence in this experiment comes from the green fluorescence protein 
(GFP) encoded by the pDNA used. A cell that gives a green fluorescence signal has 
undergone transfection. The transfection efficiency is the percentage number of positive 
fluorescent cells of the total number of cells. The results show the transfection efficiency 
of the NPs was below 10%. 
 
Figure 15. Transfection efficiency of different PLGA NPs 
3.6 Fluorescence correlation spectroscopy (FCS) of cationic PLGA NPs 
FCS is a microscopy technique that monitors the fluorescence intensity fluctuations of 
fluorescently labeled molecules which diffuse in and out of the focal volume of a confocal 
microscope. The free fluorescently labeled alexa647-siRNA molecules are present in the 
focal volume considered as the reference signal (baseline) and it represents as the initial 
concentrations of siRNA. Upon complexation of cationic PLGA NPs with alexa647-siRNA, 
the fluorescence signal decreases with some high fluorescence intensity peak compared 
to reference signal of initial siRNA. When siRNA releases from the complexes, the 
concentration of the free alexa647-siRNA increases leading to an increase in the 
fluorescence signal with decreased peak intensity compared to the signal of the 
complexes. FCS can be used to quantitatively determine the encapsulation and release of 
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any fluorescent labeled molecule. In the present study, labeled alexa647-siRNA is 
complexed with cationic PLGA NPs and their release profile was studied at different time 
points. It can be observed that the fluorescence intensity decreases when alexa647-
siRNA complexes with cationic PLGA NPs shown in Figure 16 and Figure 17. The 
decreased fluorescence with peak was observed after long incubation time. 
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Figure 16. Fluorescence intensity of free labeled siRNA (A); labeled siRNA + PLGA Chitosan (B); 
labeled siRNA + PLGA Chitosan after 1 h (C); labeled siRNA + PLGA Chitosan after 2 h (D); labeled 
siRNA + PLGA Chitosan after 24 h (E) 
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The release of siRNA from the cationic NPs can be controlled by several measurements 
performed in defined time intervals.  
By observing the Figure 17 (A) we can see the condensed siRNA inside the protamine 
coated PLGA NPs once the fluorescence intensity is lower and the formation of peaks 
occurred. Figure 17 (B) and (C) show increasing fluorescence intensity probably due to 
partial libertation of the siRNA from the nanoparticles. Figure 17 (D) shows the diminishing 
of the fluorescence intensity indicating that the siRNA is probably still encapsulated inside 
the NPs even after prolonged dispersion in Hepes buffer. 
The same experiment was also performed with PLGA Protamine NPs. 
 
Figure 17. Fluorescence intensity of labeled siRNA + PLGA Protamine NPs (A); labeled siRNA + PLGA 
Protamine NPs after 1 h (B); labeled siRNA + PLGA Protamine NPs after 2 h (C); labeled siRNA + PLGA 
Protamine after 24 h (D) 
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The percentage of release of the siRNA from the nanoparticles observed over time is 
displayed in Figure 18. 
 
Figure 18. Percentage of release of siRNA over time 
The siRNA release kinetics shown in Figure 18 where at time 0h, we can observe the 
association of siRNA with cationic PLGA NPs. Chitosan coated PLGA NPs shows higher 
complexation, about 60%, of siRNA, after 24 h it releases to about 14.7%. In case of 
protamine coated PLGA NPs, shows complexation until 1 h and then release slowly of 
3.8% until 24 h of incubation.  
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3.7 Single Particle Tracking (SPT) of cationic PLGA NPs 
SPT tracks the movement of fluorescently labeled NPs and by observing its trajectories in 
solution it is possible to obtain information about the size of the particles and their 
interactions with the surroundings. The cationic PLGA NPs complexed with pDNA labeled 
with GFP were analyzed and their size and movement were assessed. The protamine 
coated cationic PLGA NPs is shown in Figure 19. It was difficult to analyze chitosan 
coated PLGA NPs via SPT due to insufficient number of tracks to analyze the trajectories 
and the right size of the particles. 
 
Figure 19. SPT analysis of PLGA + Protamine NPs complexed with pDNA 
3.8 Incorporation of Quantum Dots in PLGA NPs 
To improve the imaging potential of the prepared NPs, QDs were added to the PLGA 
solution, to enable its incorporation in the core of the PLGA NPs. The following 
experiments were performed with these NPs to observe their physic-chemical behavior. 
3.8.1 Dinamyc light scattering and UV-Vis measurements 
Different concentrations of QDs were evaluated to assess the changes in size, zeta-
potential and toxicity of the QDs PLGA NPs.  
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Figure 20. Average size of PLGA QDs NPs 
 
Figure 21. Average zeta-potential of PLGA QDs NPs 
Both for size and zeta-potential, no major differences were observed between the different 
volumes tested. 
3.8.1.1 PLGA QDs NPs positively coated with Chitosan or Protamine 
The size and surface charge of the PLGA QDs NPs coated with chitosan and protamine 
are shown in Figure 22 and 23. The results indicate that the higher size and zeta-potential 
is obtained for the PLGA QDs coated with chitosan (≈ 200 nm; ≈ 60 mV) compared to the 
one with protamine (≈ 150 nm; ≈ 25 mV). In order to observe the absorbance of the PLGA 
QDs NPs, UV-Vis measurements were performed but no major difference was observed. 
The UV-Vis spectrum of PLGA QDs NPs varied with different volumes of QDs as can be 
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seen in Figure 24. Upon increasing the QDs volume, the absorbance intensity increased 
and thus imaging properties of the NPs are also expected to be better. However, 
photoluminescence measurement is needed for better characterization of the PLGA QDs 
NPs system for imaging applications. 
 
 
Figure 22. Average size of PLGA QDs NPs positively coated with Chitosan or Protamine 
 
Figure 23. Average Zeta-potencial of PLGA QDs NPs positively coated with Chitosan or Protamine 
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Figure 24. UV-Vis spectrum of PLGA NPs with different volumes of QDs 
3.9 Complexation of pDNA with the cationic PLGA QDs NPs 
The binding potential of the PLGA QDs NPs with pDNA was assessed by performing the 
gel electrophoresis and the images were obtained under UV-light. 
3.9.1 Chitosan coated PLGA QDs NPs 
The result obtained in Figure 25 indicates that chitosan coated PLGA QDs NPs could 
complex pDNA from 6 µg onwards. 
 
Figure 25. Photo of Gel Electrophoresis of pDNA with PLGA QDs Chitosan NPs 
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3.9.2 Protamine coated PLGA QDs NPs 
In case of protamine coated PLGA QDs NPs, they could complex pDNA from 18 µg 
onwards as shown in Figure 26. This result is in coherence with zeta-potential result 
where chitosan coated PLGA QDs NPs show higher positive charge compared to 
protamine hence complexation with pDNA also starts at lower amount of NPs. 
 
 
Figure 26. Photo of Gel Electrophoresis of pDNA with PLGA QDs Protamine NPs 
 
3.10 Cytotoxicity of the PLGA QDs NPs 
The results of viability of HeLa cells after exposure to PLGA QDs NPs are represented in 
the Figure 27. It was observed that the PLGA NPs incorporated with up to 7.5x10-4 µM of 
QDs, did not impart cytotoxicity to the cells.  
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Figure 27. Percentage of viability of HeLa cells after exposure to PLGA QDs NPs 
3.11.1 Cytotoxicity of chitosan coated PLGA QDs NPs 
The chitosan coated cationic PLGA QDs NPs at different amounts when incubated with 
HeLa cells showed to provoke a moderate decrease of the viability as compared with 
controls, although no conclusions can be taken due to the low number of replicates made.  
 
Figure 28. Percentage of viability of HeLa cells after exposure to PLGA QDs Chitosan NPs 
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3.11.2 Cytotoxicity of protamine coated PLGA QDs NPs 
The protamine coated cationic PLGA QDs NPs up to 60 µg did not show toxicity towards 
HeLa cells. 
 
Figure 29. Percentage of viability of PLGA QDs Protamine NPs 
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4. Discussion 
In the present work, the synthesis and characterization of PLGA and gold nanoparticles 
was performed with different polymeric coatings to obtain particles with cationic charges 
and imaging properties. 
The size variance of the AuNPs was investigated, leading to the conclusion that by 
varying the concentration of HAuCl4 and reducing/co-reducing agents, different sizes can 
be achieved. The results obtained show that the most stable AuNPs are the ones 
prepared at room temperature upon using sodium citrate and sodium borohydride. Polte 
et al., 2010 studied the differences in the two synthesis methods of AuNPs, by using 
sodium citrate (“slow” reaction) or NaBH4 (“fast” reaction) (83). Using simultaneously the 
two reducing agents, we took advantage of the fast reaction provoked by NaBH4 and the 
monodispersity of the particles offered by sodium citrate, therefore obtaining AuNPs with 
the best characteristics for our study. Unfortunately, these particles could not be tested for 
cytotoxicity due to time constraints. Hence, a detailed biological investigation needs to be 
performed for their potential utilization in therapeutics.  
To characterize the PLGA NPs with and without different polymeric coatings, several 
assays were performed. The size and zeta-potential results on the prepared PLGA NPs 
indicated that the size of PLGA NPs increases with the increasing concentration of the 
PLGA solution used in their preparation as already showed by Kara et al, 2014 (87). 
Cationic polymers chitosan and protamine were used for surface modifications to 
tentatively enhance biodistribution and pharmacokinetic profile, leading to the increase in 
size and positive zeta-potential. The chitosan coated PLGA NPs contributed to a higher 
size, ≈ 200 nm, than protamine coated PLGA NPs, ≈ 150 nm. Baoum et al., 2010 also 
modified the surface of PLGA NPs with chitosan or protamine and obtained similar sizes 
for chitosan coating (201 nm). Regarding zeta-potential, they have obtained +36.8 mV 
with chitosan coating and +17.7 mV with protamine coating, which can be related to the 
values we obtained, ≈ +40 mV for chitosan coating and ≈ +20 mV for protamine coating. 
Size of chitosan coating and zeta-potential values are similar to the ones we obtained, 
specially regarding the difference between the higher zeta-potential conferred by chitosan 
coating when compared with protamine one (84). 
Gel electrophoresis of pDNA complexed with different concentrations of chitosan coated 
PLGA NPs was performed and it was observed that the NPs from 8 µg onwards show 
good complexation ability (Figure 10). In case of the protamine coated PLGA NPs, the 
complete complexation occurs at NPs amount of 18 µg onwards (Figure 11). 
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The cytotoxicity of the PLGA NPs was assessed using the MTT assay. It was observed 
that up to 400 µg of PLGA NPs no toxicity was observed towards HeLa cells. When 
considering chitosan coated cationic PLGA NPs, no toxicity was observed after incubation 
of the HeLa cells with different amounts of NPs. For protamine coated PLGA NPs the 
cytotoxicity elicited by these particles was higher than we predicted and the viability of the 
cells were found to be lower than 70% after 3 hours of incubation with the higher 
concentrations tested. This result was unexpected since it has already been reported by 
Arbab et al., that low concentrations of protamine does not show toxicity. In this study, 
protamine sulfate at concentration up to 50 µg/mL was incubated with different cell types 
and MTT assay was performed showing no significant loss of viability. The differences 
seen between both studies can be the concentrations of the solution of protamine used, 
once our concentration was higher (1 mg/mL) than the maximum tested (50 µg/mL) by 
Arbab et al. (85). 
The transfection efficiency assay was performed to evaluate the effect of the cationic 
coating, of the NPs complexed with pDNA, on the internalization of the nucleic acid into 
the cells. The results of this experiment, both regarding PLGA chitosan NPs and PLGA 
protamine NPs, showed low transfection efficiency, below 10%. It was already reported by 
Martínez Gómez et al., that protamine coated PLGA microparticles facilitate cell 
penetration of antigen delivery systems (80). The microparticles used in the study of 
Martínez Gómez had a much higher size (5.3 µm) than the NPs used in our study (505 nm 
according to SPT results), as well as zeta-potential (+64.8 mV and +20 mV respectively). 
These differences can explain the results we obtained once the conclusion reached by 
Martínez Gómez was that the transfection efficiency was size dependent and only 
protamine-coated microparticles, which were the biggest, were able to transfect HEK 
cells.    
FCS was performed to see the complexation of the nanoparticles with alexa647-siRNA 
and the release profiles of siRNA. The association potential was about 60% when 
considering chitosan coated PLGA NPs and 93 % for protamine coated PLGA NPs. The 
release rates from both particles after 24 hours were relatively low, showing the high 
complexation potential between the particles and the siRNA. Jagani et al., 2012 studied 
the siRNA encapsulation efficiency into chitosan coated PLGA NPs and obtained an 
association potential of 46.7% and a release rate of the siRNA after 24 hours of 
approximately 40%. The association potential can be compared to what we have obtained 
although our release rate was much lower, 14.7%, maybe because the concentrations of 
PLGA (2 mg/mL) and chitosan (0.4 mg/mL) used by the other authors (86) for the 
Discussion  
 
46 
 
preparation of the NPs were different from the ones we used, 8mg/mL and 1 mg/mL 
respectively.  
The SPT was made to confirm the nanoparticles size and to see their trajectories and 
movement in HEPES buffer. The size of the protamine coated PLGA NPs was higher than 
when measured with DLS but this result is expected due to the complexation of pDNA, 
which turns the particle into bigger dimensions. The data regarding chitosan coated PLGA 
NPs was not enough to take conclusions due to the insufficient number of tracks to 
analyze trajectories and subsequently the nanoparticles’ size. 
Aiming to improve imaging properties of the nanoparticles prepared, QDs were added to 
the prepared PLGA solution, incorporating them inside the core of the PLGA NPs, coated 
either with chitosan or protamine. The size and zeta-potential of these particles was not 
affected by the addition of QDs, once they have small dimensions (13.4 nm) as compared 
with the PLGA NPs. The complexation potential of these nanoparticles with pDNA was 
also assessed. The ability to complex pDNA was observed from 6 µg of NPs coated with 
chitosan onwards and from 18 µg onwards in case of protamine. Regarding cytotoxicity, 
the particles didn’t show toxicity to HeLa cells up to 7.5x10-4 µM of QDs used. The 
chitosan coated PLGA QDs NPs also didn’t impart toxicity to cells as well as protamine 
coated PLGA QDs NPs. 
All the assays should be repeated and more toxicity assays should be made to confirm 
the MTT results, both regarding to positively coated PLGA NPs and PLGA QDs NPs.  
 
Conclusions  
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5. Conclusions  
In the present research a new approach has been adopted for synthesis of inorganic 
AuNPs and organic biodegradable PLGA NPs.  
Monodispersed AuNPs were synthesized at room temperature by simultaneously using 
two different reducing agents (Sodium citrate and Sodium borohydride) and showed to be 
more stable and reproducible when compared to those prepared by the conventional 
method.  
The adopted preparation technique of the organic biodegradable PLGA NPs offers better 
control over size, polydispersity index and surface charge. 
The prepared PLGA NPs surface was modified with cationic polymers chitosan or 
protamine via carbodiimide chemistry, and QDs were incorporated.  
The cytotoxicity analysis of the prepared nanocarriers showed no remarkable toxic effects 
to HeLa cells.  
The cationic PLGA NPs showed good nucleic acid complexation ability although did not 
show good transfection potential.  
The utilization of the prepared nanocarriers has to be investigated further in detail.  
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Supplement 1 
 
Table 4 DLS measurements of AuNPs formed using Sodium citrate in different concentrations and 
temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate 
177.1 0.225 
Room 
temperature 
 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate 
26.89 0.572 
Room 
temperature 
1mL HAuCl4  + 1mL H2O 
+ 500µL Sodium citrate 
58.41 0.273 90°C 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate 
24.08 0.348 90°C 
2mL HAuCl4 + 2mL 
Sodium citrate 
225.6 0.371 90°C 
2mL HAuCl4 + 5mL 
Sodium citrate 
14.57 0.570 90°C 
2mL HAuCl4 + 2mL H2O + 
1mL Sodium citrate 
95.65 0.182 90°C 
2mL HAuCl4 + 2mL H2O + 
2mL Sodium citrate 
17.86 0.611 
Room 
temperature 
1mL HAuCl4  + 1mL H2O 
+ 500µL Sodium citrate 
65.34 0.270 90°C 
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1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate 
20.11 0.626 90°C 
1mL HAuCl4  + 1mL H2O 
+ 500µL Sodium citrate 
131.6 0.091 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate 
40.06 0.434 
Room 
temperature 
 
 
 
Table 5 DLS measurements of AuNPs formed using Sodium citrate and NaBH4 in different 
concentrations and temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
2mL HAuCl4 + 2mL 
Sodium citrate + 1mL 
NaBH4 
48.53 0.234 
90°C 
 
2mL HAuCl4 + 2mL 
Sodium citrate + 1mL 
NaBH4 
20.15 0.647 0°C 
2mL HAuCl4 + 2mL 
Sodium citrate + 1mL 
NaBH4 
29.64 0.349 
Room 
temperature 
2mL HAuCl4 + 2mL 
Sodium citrate + 500µL 
NaBH4 
37.95 0.904 
Room 
temperature 
2mL HAuCl4 + 2mL 
Sodium citrate + 500µL 
NaBH4 
43.875 0.672 0°C 
2mL HAuCl4 + 2mL 
Sodium citrate + 300µL 
NaBH4 
57.09 0.655 90°C 
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2mL HAuCl4 + 2mL 
Sodium citrate + 500µL 
NaBH4 
20.99 0.658 90°C 
2mL HAuCl4 + 1mL 
Sodium citrate + 500µL 
NaBH4 
63.96 0.648 90°C 
2mL HAuCl4 + 2mL 
Sodium citrate + 1mL 
NaBH4 
23.1 0.684 90°C 
2mL HAuCl4 + 2mL 
Sodium citrate + 1mL 
NaBH4 
42.89 1 90°C 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
20.9 0.272 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
17.19 0.293 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
30.76 0.215 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
22.02 0.338 90°C 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
38.62 0.196 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
69.57 0.149 90°C 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
28.59 0.100 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
22.50 0.183 90°C 
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100µL NaBH4 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
41.66 0.094 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
142.4 0.283 90°C 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
29.58 0.203 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
19.09 0.438 90°C 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
158.7 0.253 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
64.85 0.138 90°C 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
18.60 0.258 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
48.08 0.106 90°C 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
41.43 0.215 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
41.08 0.206 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
16.66 0.199 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 17.83 0.339 Room 
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1mL Sodium citrate + 
100µL NaBH4 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
18.49 0.320 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
18.12 0.316 
Room 
temperature 
1mL HAuCl4 + 500µL 
Sodium citrate + 200µL 
NaBH4 
41.11 0.198 
Room 
temperature 
1mL HAuCl4 + 500µL 
Sodium citrate + 200µL 
NaBH4 
38.47 0.192 
Room 
temperature 
2mL HAuCl4 + 2mL H2O + 
1mL Sodium citrate + 
400µL NaBH4 
157.8 0.248 
Room 
temperature 
2mL HAuCl4 + 2mL H2O + 
2mL Sodium citrate + 
200µL NaBH4 
53.97 0.275 90°C 
2mL HAuCl4 + 2mL H2O + 
2mL Sodium citrate + 
100µL NaBH4 
23.89 0.508 90°C 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
94.32 0.158 90°C 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
54.61 0.577 90°C 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
17.74 0.280 90°C 
1mL HAuCl4 + 1mL H2O + 
500µL Sodium citrate + 
200µL NaBH4 
28.14 0.404 
Room 
temperature 
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1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
25.86 0.169 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
50µL NaBH4 
17.61 0.453 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
200µL NaBH4 
33.89 0.269 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
1mL Sodium citrate + 
100µL NaBH4 
45.07 0.240 
Room 
temperature 
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Table 6 DLS measurements of AuNPs formed using NaBH4 in different concentrations and 
temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
1mL HAuCl4 + 1mL H2O + 
50µL NaBH4 
22.94 0.541 
Room 
temperature 
 
1mL HAuCl4 + 1mL H2O + 
200µL NaBH4 
482.2 0.551 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
100µL NaBH4 
90.13 0.141 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
50µL NaBH4 
60.74 0.396 
Room 
temperature 
 
 
Table 7 DLS measurements of AuNPs formed using NaBH4 and CTAB in different concentrations and 
temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
200µL HAuCl4 + 
200µL CTAB 
55.27 0.236 
 
90°C 
 
1mL HAuCl4 + 1mL 
H2O + 200µL NaBH4 
+ 500µL CTAB 
103.4 0.432 Room temperature 
1mL HAuCl4 + 1mL 
H2O + 100µL NaBH4 
+ 1mL CTAB 
126.4 0.407 Room temperature 
1mL HAuCl4 + 1mL 
H2O + 100µL NaBH4 
+ 1mL CTAB 
126.4 0.407 Room temperature 
1mL HAuCl4 + 1mL 
H2O + 50µL NaBH4 
+ 1mL CTAB 
166.4 0.431 Room temperature 
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Table 8 DLS measurements of AuNPs formed using bPEI in different concentrations and temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
1mL HAuCl4 + 1mL H2O + 
(25µL of bPEI + 75µL 
H2O) 
790.1 0.717 
90°C 
 
1mL HAuCl4 + 1mL H2O + 
(25µL bPEI + 75µL H2O) 
1718 1 90°C 
2mL HAuCl4 + 100µL 
bPEI 
260.1 0.314 90°C 
1mL HAuCl4 + 1mL H2O + 
(25µL bPEI + 75µL H2O) 
289.8 0.345 90°C 
1mL HAuCl4 + 1mL H2O + 
(50µL bPEI + 50µL H2O) 
2002 1 90°C 
1mL HAuCl4 + 1mL H2O + 
(75µL bPEI + 75µL H2O) 
196 0.377 90°C 
1mL HAuCl4 + 1mL H2O + 
(25µL bPEI + 75µL H2O) 
42.59 0.118 90°C 
 
 
 
Table 9 DLS measurements of AuNPs formed using Oleic acid or Olive oil in different concentrations 
and temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
1mL HAuCl4 (solution 
1mg/mL in acetone) + 
100µL Oleic acid 
637.1 0.480 
Room 
temperature 
 
1mL HAuCl4 + 1mL H2O + 
2µL Olive oil 
291.4 0.415 
Room 
temperature 
1mL HAuCl4 + 1mL H2O + 
100µL Olive oil 
101.6 0.358 
Room 
temperature 
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Table 10 DLS measurements of AuNPs formed using NaBH4 and Alginic acid in different 
concentrations and temperatures 
Composition Size (d.nm) PDI 
Temperature 
conditions 
1mL HAuCl4 + 1mL H2O + 
1mL Alginic acid 
242 0.289 
90°C 
 
1mL HAuCl4 + 1mL H2O + 
200µL Alginic acid + 
600µL NaBH4 
41.4 0.265 90°C 
1mL HAuCl4 + 1mL H2O + 
250µL Alginic acid + 
50µL NaBH4 
44.97 0.247 90°C 
1mL HAuCl4 + 1mL H2O + 
250µL Alginic acid + 
250µL NaBH4 
95.03 0.417 90°C 
1mL HAuCl4 + 1mL H2O + 
250µL Alginic acid + 
500µL NaBH4 
79.20 0.495 90°C 
1mL HAuCl4 + 1mL H2O + 
2500µL Alginic acid + 
1mL NaBH4 
26.53 0.556 90°C 
1mL HAuCl4 + 1mL H2O + 
250µL Alginic acid + 
100µL NaBH4 
45.45 0.263 90°C 
1mL HAuCl4 + 1mL H2O + 
250µL Alginic acid + 
400µL NaBH4 
50.17 1 90°C 
1mL HAuCl4 + 1mL H2O + 
200µL Alginic acid + 
600µL NaBH4 
45.95 0.193 90°C 
1mL HAuCl4 + 1mL H2O + 
250µL Alginic acid + 
50µL NaBH4 
39.25 0.373 90°C 
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